This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

written by researcher(s)

proofread

COVID is running rampant in China—but herd immunity remains elusive

COVID is running rampant in China—but herd immunity remains elusive
Credit: AI-generated image (disclaimer)

After nearly three years of keeping COVID under control, China is experiencing a massive new wave of COVID infections. The official figures reporting 60,000 deaths between December 8 and January 12 are widely seen as underestimating the impact of the outbreak.

Until December 2022, China had used lockdown policies to reduce the opportunity for COVID spread in the hope of eliminating the virus or building up enough immunity through vaccination. The exceptionally strict zero-COVID policy was very successful in stopping the virus' spread while the world faced returning deadly waves.

However, the prolonged lockdowns eventually became politically and economically unsustainable. China's official policy is currently concentrating on strengthening the early detection and treatment of severe cases rather than the prevention of infections. This has led to claims the country is now pursuing a "herd immunity" approach.

But would this be a realistic goal? Lessons from other countries' experiences suggest not. Let's take a look at why.

Herd immunity: A recap

The concept was introduced some 100 years ago to explain why epidemic waves often stop before affecting the whole population.

As a disease such as COVID spreads, more people become infected. Most of them recover and gain infection-induced immunity. Those who become infected increasingly have contact with immune rather than susceptible people. This leads to lower risk of passing on the infection.

COVID is running rampant in China—but herd immunity remains elusive
The 5% vaccination-induced immunity level, shown here for illustration purposes, reflects the limited booster coverage and the lower efficacy and faster waning of China’s vaccines. Credit: Adam Kleczkowski

The epidemic wave slows down and eventually declines. The decline is caused by a sufficiently large number of people becoming immune, therefore protecting the whole population—or the "". In the 1970s, epidemiologists found a simple formula that predicts the proportion of immune individuals at which the number of infections stops growing.

The formula includes the R number, the average number of people one infected person passes the disease onto. Non-pharmaceutical interventions, like social distancing, lockdowns, or mask-wearing, are aimed at reducing the transmissibility of the virus, lowering the value of R.

The herd immunity threshold also depends on the proportion of people with pre-existing immunity from either previous outbreaks or vaccination. Using these concepts, scientists have designed that successfully keep such as smallpox, polio, diphtheria and rubella under control.

For such public health policies to be successful, mass vaccination needs to reach a high proportion of the population. Sublineages of the omicron variant BA.5 are currently dominant in China. Omicron has an average R of 9.5, so around 90% of the population needs to be fully protected to reach herd immunity, according to the model.

However, vaccination is not perfect. Some 89% of China's population has so far reportedly received two doses of the vaccine. But booster uptake is low and the efficacy of the Sinovac and Sinopharm vaccines used in China is lower than the mRNA vaccines from Pfizer and Moderna used widely. So, the actual percentage of people protected by the vaccine will be lower than in other countries—perhaps as low as 5%.

Before December 2022, China had seen relatively few COVID cases, leaving infection-induced immunity low. This creates a significant gap between the existing levels of immunity and those required to achieve herd immunity, as illustrated in the figure below. In the absence of other control measures, this gap will need to be filled in by infection, resulting in a massive outbreak.

COVID is running rampant in China—but herd immunity remains elusive
Credit: Institute for Health Metrics and Evaluation, University of Washington and Adam Kleczkowski

Predictions are challenging

Predicting what will happen next in China is difficult due to the lack of reliable data. Although cases now seem to be decreasing, the traditional activity around the lunar new year will most likely cause a new wave.

Several models have explored different assumptions. The Institute for Health Metrics and Evaluation expects almost three million cases per day at an upcoming peak following the lunar new year and 1.6 million deaths by the end of 2023.

Health data analytics company Airfinity predicts four million cases per day at the peak of the upcoming wave, and that the number of deaths could reach 2.1 million. Given the uncertainty about the epidemic spread in China, these numbers might even be underestimates.

Eventually, China's population will temporarily reach the "herd immunity" level, and the upcoming wave will probably peak around March 2023, according to these models. But this is not a guarantee that the epidemic will end there.

The virus persists even in countries like the UK, where roughly 80%–95% of the population have COVID antibodies. This indicates high levels of immunity from prior , vaccination, or both.

Unfortunately, the immunity from COVID vaccines and prior infections wanes after some months and may be less durable against new variants. As a result, new waves appear as herd immunity is temporarily breached, before being restored again.

If China is really aiming at herd immunity to eliminate the virus—and some young Chinese people are apparently seeking infection—it will very likely fail again. The repeated lesson from other countries is that the loss of immunity and the appearance of new variants make herd immunity a futile goal when it comes to COVID.

Provided by The Conversation

This article is republished from The Conversation under a Creative Commons license. Read the original article.The Conversation

Citation: COVID is running rampant in China—but herd immunity remains elusive (2023, January 23) retrieved 21 July 2024 from https://medicalxpress.com/news/2023-01-covid-rampant-chinabut-herd-immunity.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Is omicron leading us closer to herd immunity against COVID?

4 shares

Feedback to editors